Comparative Pharmacology
Head-to-head clinical analysis: LOGILIA versus NORETHIN 1 35E 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOGILIA versus NORETHIN 1 35E 21.
LOGILIA vs NORETHIN 1/35E-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lorecivivt, the active component of Logilia, is a small interfering RNA (siRNA) that targets the synthesis of transthyretin (TTR) protein. It binds to a genetically conserved sequence in the 3' untranslated region of mutant and wild-type TTR mRNA, leading to its degradation via RNA interference. This reduces TTR protein production and deposition in tissues.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release from pituitary, inhibits ovulation, thickens cervical mucus, alters endometrial lining.
100 mg orally once daily.
1 tablet orally once daily for 21 days, followed by 7 days off, then repeat. Each tablet contains 1 mg norethindrone acetate and 0.035 mg ethinyl estradiol.
None Documented
None Documented
Terminal elimination half-life: 12–15 hours; dose adjustment recommended in renal impairment
Norethindrone: terminal half-life ~7-8 hours (range 5-12 h). Ethinyl estradiol: terminal half-life ~13-27 hours (mean ~17 h). The half-life supports once-daily dosing with stable serum concentrations achieved after 3-5 days.
Approximately 60% renal (as unchanged drug), 40% biliary/fecal
Norethindrone and ethinyl estradiol are primarily excreted via urine (approximately 60-80% as metabolites) and feces (about 10-30%). Renal excretion accounts for the majority, with biliary/fecal elimination contributing a minor but significant fraction.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive